Background: Peripheral blood progenitor cells can be mobilized using cytotoxic chemotherapy and cytokines. We were looking for predictive parameters indicating a patient’s response to a given mobilization regimen. Patients and Methods: Flow cytometry analysis and clonogenic assays were used to examine hematopoietic progenitor cells in bone marrow and peripheral blood prior to G-CSF-supported chemotherapy and were compared to CD34+ cell counts in peripheral blood and leukapheresis products in the recovery phase. Stroma-dependent long-term cultures were performed from steady-state bone marrow and leukapheresis product samples. 90 patients (24 non-Hodgkin’s lymphoma, 5 Hodgkin’s disease, 33 multiple myeloma, 28 solid tumor) were included in this study. Results: A correlation analysis revealed steady-state peripheral blood CD34+ cells (all patients: r = 0.59, p < 0.0001; non-Hodgkin’s lymphoma, r = 0.7, p = 0.0003; multiple myeloma: r = 0.71, p < 0.0001) and peripheral blood colony-forming cells but not their bone marrow counterparts to be a measure of a patient’s mobilizable CD34+ cell number which may reflect different degrees of blood dilution in the bone marrow aspirates. The proliferative potential of primitive stem cell clones in the CD34+ population was comparable between steady-state bone marrow and mobilized peripheral blood cells. An increasing number of chemotherapy cycles prior to mobilization lead to a depletion of CD34+ cells from steady-state peripheral blood (p = 0.001), mobilized peripheral blood (p = 0.0001), or the mean leukapheresis product CD34+ cell yield (p = 0.0021). Steady-state peripheral blood CD34+ cell counts could be related to the individual progenitor cell yields. In order to obtain in one leukapheresis product 2.5 × 106 CD34+ cells/kg body weight, a steady-state peripheral blood CD34+ cell count of 0.6 × 106/l and 0.16 × 106/l were required if regular (10 l) and large-volume (median 20 l) leukaphereses were performed, respectively. Conclusion: These results contribute to the further optimization of stem cell therapy since – depending on the tumor entity – they allow to estimate the expected stem cell yield before the mobilization therapy is administered.

This content is only available via PDF.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.